Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.…
Adherex Technologies Q3 Earnings Call Highlights
Fennec Pharmaceuticals (NASDAQ: FENC) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 35 employees.
The shares were at 13.09 USD on 20 November 2026, up 64.0% over 52 weeks. Its 52-week range is 5.650 USD to 13.85 USD: the price is 5.5% below the high and 131.7% above the low.
At a market capitalisation of 462.14M USD, it trades at 436.3 times trailing earnings and 12.5 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a premium of 1217% for FENC.
Fennec Pharmaceuticals reports return on equity of -27.5%, an operating margin of 5.6% and revenue up 57.3% year over year.
It holds more cash than debt, a net cash position of 48.68M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. 5 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 17.60 USD is 34.5% above the current price. The next earnings report is expected on 23 March 2027.